Skip to content
Screener

Beta Bionics BBNX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$19.81M+59.3%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$234.79M+67.5%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%
Debt / equity0.0×
Current ratio8.9×-5.8×

Where this comes from

Reported directly by Beta Bionics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Change in fair value of warrant liabilities(12,450)
Total other income (expense), net2,1753,0034,551(7,011)
Net loss$(23,403)$(16,869)$(45,298)$(45,525)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term and long-term investments(294)(91)(793)84
Comprehensive loss$(23,697)$(16,960)$(46,091)$(45,441)
Net loss per share attributable to common stockholders, basic and diluted$(0.53)$(0.39)$(1.02)$(1.23)
Weighted-average common shares outstanding, basic and diluted44,545,29343,390,65244,554,14137,087,726

Item 1. Financial Statements.

FAQ

What is Beta Bionics's comprehensive income (loss), net of tax, attributable to parent?
Beta Bionics (BBNX) reported comprehensive income (loss), net of tax, attributable to parent of -$23.7M in Q2 2026.
How has Beta Bionics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Beta Bionics's comprehensive income (loss), net of tax, attributable to parent decreased by 39.7% year-over-year, from -$16.96M to -$23.7M.
What is the long-term trend for Beta Bionics's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2023 to 2025), Beta Bionics's comprehensive income (loss), net of tax, attributable to parent has grown at a 28.7% compound annual growth rate (CAGR), from -$43.96M to -$72.86M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity during a period resulting from transactions and other events from non-owner sources. It encompasses both net income and other comprehensive income items, such as unrealized gains or losses on securities. It provides a holistic view of the company's financial performance by including all recognized revenues, expenses, gains, and losses.

Ask your AI about Beta Bionics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude